153 completed, 12 terminated, 8 recruiting, 6 withdrawn. 187 Phase 1, 54 Phase 2.
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation VX-581 - Cystic Fibrosis | Phase 1 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 16 | 2026-09-23 | 2026-10-27 |
| Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection AchromoPhage - Cystic Fibrosis (CF), Achromobacter Infection | Phase 1 | Recruiting | Ghady Haidar | 12 | 2026-08-20 | 2026-10-08 |
| Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants VX-272, Placebo, Tezacaftor - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 160 | 2026-02-25 | 2026-09-23 |
| Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants VNZ/TEZ/D-IVA, Rosuvastatin - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 18 | 2026-01-12 | 2026-04-02 |
| Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics - CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection | Phase 1 | Not yet recruiting | University of California, San Diego | 30 | 2025-12-31 | 2025-12-12 |
| Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis VX-581, Placebo, D-IVA - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 152 | 2025-12-09 | 2026-10-19 |
| Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants. SION-451, SION-2222, SION-109 - Cystic Fibrosis (CF) | Phase 1 | Completed | Sionna Therapeutics Inc. | 120 | 2025-07-23 | 2026-09-10 |
| A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON) BI 3720931 - Cystic Fibrosis | Phase 1 / Phase 2 | Active not recruiting | Boehringer Ingelheim | 5 | 2025-05-20 | 2026-04-14 |
| A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation VX-828 - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 68 | 2025-04-01 | 2025-06-04 |
| A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1) BI 3720931, Placebo, Inhaler - Cystic Fibrosis | Phase 1 / Phase 2 | Terminated | Boehringer Ingelheim | 5 | 2024-11-04 | 2026-04-15 |
| A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects KIT2014, Placebo - Cystic Fibrosis | Phase 1 | Completed | Kither Biotech Srl | 56 | 2024-10-16 | 2025-08-05 |
| A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) SP-101 and doxorubicin Cohort 1, SP-101 and doxorubicin Cohort 2 - Cystic Fibrosis | Phase 1 / Phase 2 | Recruiting | Spirovant Sciences, Inc. | 15 | 2024-09-16 | 2024-11-25 |
| A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis CMTX-101, Placebo - Persistent Infection, Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Clarametyx Biosciences, Inc. | 43 | 2024-06-24 | 2026-10-30 |
| A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation VX-118 - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 15 | 2024-04-02 | 2024-06-03 |
| A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection RSP-1502, Tobramycin inhalation solution - Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic | Phase 1 / Phase 2 | Completed | Respirion Pharmaceuticals Pty Ltd | 71 | 2024-04-01 | 2026-06-25 |
| A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists VNZ/TEZ/D-IVA - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 10 | 2024-03-26 | 2024-05-16 |
| A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA) VNZ/TEZ/D-IVA - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 34 | 2024-03-13 | 2025-09-26 |
| Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis VX-828, Placebo, Itraconazole - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 165 | 2023-12-12 | 2026-08-10 |
| Phase 1 Study to Assess Safety and Efficacy of ANG003 ANG003 - Exocrine Pancreatic Insufficiency | Phase 1 | Completed | Anagram Therapeutics, Inc. | 57 | 2023-08-25 | 2026-04-27 |
| A Study Assessing KB407 for the Treatment of Cystic Fibrosis KB407 (Nebulization) - Cystic Fibrosis | Phase 1 | Recruiting | Krystal Biotech, Inc. | 20 | 2023-06-30 | 2026-05-07 |
Showing 20 of 187. Sign in to see all of them.
Respiratory Tract Diseases (11) · Pseudomonas Infections (8) · Genetic Diseases, Inborn (7) · Pulmonary Disease, Chronic Obstructive (6) · Rare Diseases (6) · Lung Diseases (5) · Asthma (4) · Respiratory Aspiration (4) · Bronchiectasis (3) · Emphysema (3) · Respiratory Tract Infections (3) · Burkholderia Infections (2) · Digestive System Diseases (2) · Exocrine Pancreatic Insufficiency (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (187) · Infant, Newborn, Diseases (187) · Pancreatic Diseases (186) · Digestive System Diseases (185) · Lung Diseases (182) · Genetic Diseases, Inborn (180) · Respiratory Tract Diseases (176) · Pathological Conditions, Signs and Symptoms (25) · Pathologic Processes (23) · Infections (15) · Disease Attributes (14) · Bacterial Infections and Mycoses (13) · Bacterial Infections (12) · Gram-Negative Bacterial Infections (11) · Bronchial Diseases (8)
ivacaftor (14) · Inhalation (8) · Sodium Chloride (8) · deutivacaftor, tezacaftor , vanzacaftor (7) · tezacaftor (7) · Saline Solution, Hypertonic (6) · Tobramycin (6) · lumacaftor (5) · Ciprofloxacin (3) · Mannitol (3) · Sildenafil Citrate (3) · cavosonstat (3) · 4-phenylbutyric acid (2) · Genistein (2) · Itraconazole (2)
Vertex Pharmaceuticals Incorporated (25) · Flatley Discovery Lab LLC (9) · Boehringer Ingelheim (6) · Gilead Sciences (6) · Nivalis Therapeutics, Inc. (4) · Proteostasis Therapeutics, Inc. (4) · Chiesi Farmaceutici S.p.A. (3) · Insmed Incorporated (3) · Lakefront Biotherapeutics NV (3) · National Jewish Health (3) · University of Pittsburgh (3) · AlgiPharma AS (2) · Amgen (2) · AstraZeneca (2) · Case Western Reserve University (2)
United States (97) · United Kingdom (36) · Australia (17) · Germany (13) · Belgium (10) · France (10) · Canada (9) · Netherlands (9) · Czechia (4) · Israel (4) · Italy (4) · Spain (4) · Sweden (4) · Denmark (3) · New Zealand (3)
Claudia Ordonez, MD (3) · Olivier Van de Steen, MD MBA (3) · Peter Hodsman, MD (3) · Cecil Charles, PhD (2) · Eric J. Sorscher (2) · Gina Eagle, MD (2) · H. Frank Farmer, MD (2) · Jennifer L Taylor-Cousar, MD (2) · Joseph M Pilewski, MD (2) · Ronald Rubenstein, M.D., PhD. (2) · Scott Donaldson, MD (2)
PMID 33331662, PMID 37983082, PMID 31215818, PMID 27009167, PMID 32671834, PMID 35227647, PMID 37319354, PMID 12885347, PMID 15704203, PMID 17641052, PMID 20961818, PMID 21195036, PMID 23232039, PMID 23749840, PMID 23905576, PMID 24019259, PMID 24743971, PMID 25466700, PMID 25963404, PMID 26623687, PMID 26925108, PMID 27297209, PMID 28209466, PMID 28262569, PMID 30334692, PMID 30334693, PMID 31302339, PMID 31327670, PMID 32761612, PMID 33293212, PMID 34282853, PMID 34424546, PMID 34674574, PMID 35403818, PMID 36578069, PMID 38195348, PMID 39155805, PMID 39155828, PMID 40973220, PMID 41318901
2017 (4), 2014 (3), 2016 (3), 2018 (3), 2023 (3), 2009 (1), 2015 (1), 2UM1AI104681-08 (1), P01DK058327 (1), P01HL158507 (1), P30DK089507 (1), R01DK051809 (1), R01DK099199 (1), R01HL108929 (1), U01HL131046 (1)